Bio Impact Capital LLC Avadel Pharmaceuticals PLC Transaction History

Bio Impact Capital LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$14.06 - $18.82 $1.24 Million - $1.65 Million	-87,907 Reduced 10.09%	783,242 $11 Million
Q1 2024 May 15, 2024	BUY	$12.55 - $17.22 $2.59 Million - $3.55 Million	206,163 Added 31.0%	871,149 $14.7 Million
Q4 2023 Feb 13, 2024	BUY	$9.64 - $14.59 $2.7 Million - $4.09 Million	279,996 Added 72.73%	664,986 $9.39 Million
Q2 2023 Aug 14, 2023	BUY	$8.48 - $16.48 $3.26 Million - $6.34 Million	384,990 New	384,990 $6.34 Million
Q1 2022 May 13, 2022	BUY	$5.46 - $8.29 $202,222 - $307,036	37,037 Added 9.87%	412,363 $2.82 Million
Q4 2021 Feb 11, 2022	SELL	$7.34 - $11.18 $181,107 - $275,855	-24,674 Reduced 6.17%	375,326 $3.03 Million
Q3 2021 Nov 15, 2021	BUY	$6.49 - $9.91 $2.6 Million - $3.96 Million	400,000 New	400,000 $3.92 Million

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Bio Impact Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Bio Impact Capital LLC with notifications on news.